Sjogren's Syndrome Treatment: From Symptom Management to Disease-Modifying Therapy

Sjogren's syndrome has long been considered a condition with limited treatment options — "just use artificial tears" was the standard advice for decades. That picture has changed significantly. While there is still no cure, a growing toolkit of disease-modifying therapies, targeted biologics, and evidence-based symptomatic treatments can meaningfully reduce the burden of Sjogren's and slow its progression.

This guide covers the full spectrum of Sjogren's treatment — from managing dry eyes and dry mouth to addressing systemic features like neuropathy, fatigue, and autonomic dysfunction.

---

Principles of Sjogren's Treatment

Treatment of Sjogren's is stratified by disease severity and the presence of systemic features:

---

Disease-Modifying Treatments

Hydroxychloroquine (Plaquenil)

Hydroxychloroquine is the cornerstone of Sjogren's treatment and is recommended for virtually all patients with systemic disease. It works by inhibiting toll-like receptor signaling and reducing type I interferon production — a key driver of Sjogren's pathology.

Evidence: Multiple studies have shown that hydroxychloroquine reduces fatigue, joint pain, and systemic inflammation in Sjogren's. Its effect on sicca symptoms is modest but present. Long-term use may reduce the risk of lymphoma, a serious complication of Sjogren's.

Dosing: 200–400 mg daily (weight-adjusted to ≤5 mg/kg/day to minimize retinal toxicity risk).

Monitoring: Annual ophthalmological examination for retinal toxicity after 5 years of use.

Rituximab (Rituxan)

Rituximab is an anti-CD20 monoclonal antibody that depletes B cells — the primary drivers of Sjogren's autoimmunity. It is used for patients with severe systemic disease, particularly:

• Peripheral neuropathy (including SFN)
• Vasculitis and cryoglobulinemia
• Severe cytopenias
• Renal involvement
• Lymphoma

Evidence: The TRACTISS trial (UK) and TEARS trial (France) showed modest but significant improvements in fatigue and salivary flow in patients treated with rituximab. Neurological outcomes, particularly for neuropathy, appear more robust.

Dosing: 1000 mg IV × 2 doses, 2 weeks apart; repeated every 6–12 months based on response.

IVIG (Intravenous Immunoglobulin)

IVIG is the most evidence-based treatment for Sjogren's-related neuropathy, particularly ganglionopathy and severe SFN. It works through multiple immunomodulatory mechanisms including Fc receptor blockade, complement inhibition, and regulatory T-cell induction.

Evidence: Multiple case series and small trials have shown improvement in nerve fiber density and neuropathic symptoms with IVIG in Sjogren's neuropathy.

Dosing: 2 g/kg divided over 2–5 days, repeated every 4–8 weeks.

Corticosteroids

Corticosteroids (prednisone, methylprednisolone) are used for acute inflammatory flares and severe systemic manifestations. They are not recommended for long-term maintenance due to significant side effects.

Emerging biologics

Several targeted therapies are in clinical trials for Sjogren's:

• Iscalimab (anti-CD40L) — Phase III trials ongoing
• Ianalumab (anti-BAFF-R) — Phase III trials ongoing
• Remibrutinib (BTK inhibitor) — Phase III trials ongoing

---

Symptomatic Treatment: Sicca Features

Dry eyes:

• Artificial tears — preservative-free formulations (e.g., Systane Ultra, Refresh Optive) used frequently throughout the day
• Cyclosporine eye drops (Restasis, Cequa) — reduce ocular surface inflammation; prescription required
• Lifitegrast (Xiidra) — LFA-1 antagonist; reduces T-cell-mediated ocular inflammation
• Punctal plugs — small silicone plugs inserted into the tear duct openings to reduce tear drainage
• Scleral lenses — large-diameter contact lenses that create a fluid reservoir over the cornea; highly effective for severe dry eye
• Autologous serum eye drops — made from the patient's own blood; contain growth factors that promote corneal healing

Dry mouth:

• Frequent sips of water — the simplest intervention
• Sugar-free gum or lozenges — stimulate salivary flow
• Pilocarpine (Salagen) — muscarinic agonist that stimulates secretion from remaining functional gland tissue; 5 mg 3–4 times daily
• Cevimeline (Evoxac) — similar mechanism to pilocarpine; 30 mg 3 times daily
• Biotene products — saliva substitutes for patients with minimal remaining gland function
• Meticulous dental hygiene — fluoride treatments, regular dental visits; dental decay is a major complication of xerostomia

---

Symptomatic Treatment: Systemic Features

Fatigue:

Fatigue in Sjogren's is multifactorial — driven by systemic inflammation, sleep disruption, autonomic dysfunction, pain, and depression. Management requires addressing all contributing factors:

• Hydroxychloroquine — reduces inflammatory fatigue
• Low-dose naltrexone (LDN) — emerging evidence for neuroinflammatory fatigue
• Sleep optimization — treating sleep disorders (sleep apnea, non-restorative sleep) is often transformative
• Pacing and energy management — the energy envelope model; avoiding boom-bust cycles
• Exercise — gentle, graded exercise improves fatigue in autoimmune conditions; avoid overexertion

Joint pain:

• NSAIDs — for mild to moderate arthralgia
• Hydroxychloroquine — reduces joint inflammation
• Low-dose prednisone — for flares
• Methotrexate — for persistent inflammatory arthritis

Neuropathic pain:

• Duloxetine (Cymbalta) — SNRI; evidence for neuropathic pain and fatigue
• Pregabalin (Lyrica) / Gabapentin — reduce neuronal excitability
• Tricyclic antidepressants — amitriptyline or nortriptyline at low doses
• Topical treatments — lidocaine patches, capsaicin cream for localized pain

Autonomic dysfunction (POTS, orthostatic hypotension):

• Increased salt and fluid intake — 3–5 g sodium/day, 2–3 L fluid/day
• Compression garments — waist-high compression stockings (20–30 mmHg)
• Fludrocortisone — mineralocorticoid; increases blood volume
• Midodrine — alpha-1 agonist; increases vascular resistance
• Beta-blockers (propranolol, metoprolol) — reduce heart rate in POTS
• Ivabradine — selective heart rate reduction without blood pressure effects

---

Key Takeaways

Sjogren's syndrome treatment has evolved significantly beyond artificial tears and symptomatic management. Hydroxychloroquine is the foundation for systemic disease; rituximab and IVIG are effective for severe neuropathy and vasculitis; and a growing pipeline of targeted biologics offers hope for the future. Symptomatic management of sicca features, fatigue, neuropathic pain, and autonomic dysfunction significantly improves quality of life.

---

This article is for educational purposes only and does not constitute medical advice.